Arrowhead Pharmaceuticals, Inc. (ARWR) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Pasadena, CA, United States. Le PDG actuel est Christopher R. Anzalone.
ARWR a date d'introduction en bourse 1993-12-16, 609 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $9.34B.
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Pasadena, California, that develops RNA interference (RNAi) therapeutics for the treatment of intractable diseases. The company maintains a diverse clinical pipeline targeting liver diseases, metabolic disorders, cardiovascular conditions, respiratory diseases, and rare genetic disorders, with candidates in Phase 1 through Phase 3 clinical development. Key programs include ARO-AAT for alpha-1 antitrypsin deficiency, ARO-APOC3 for hypertriglyceridemia, ARO-HIF2 for renal cell carcinoma, and JNJ-3989 for chronic hepatitis B, developed under collaboration with Janssen Pharmaceuticals. Through strategic partnerships with leading pharmaceutical companies including Janssen and Takeda, Arrowhead leverages its RNAi platform technology to address genetically validated disease targets across multiple therapeutic areas.
